|
Pfizer RA Drug Could Be Delayed Past August by FDA Data Request
Pfizer’s rheumatoid arthritis (RA) candidate tofacitinib could see its review date pushed back thanks to an FDA request for an additional analysis.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives